BridgeBio Oncology Therapeutics reported total assets of $376.71M and total liabilities of $53.59M for the quarter ended Jun 2026, up 90.8% year over year. This balance sheet covers 11 quarters of results from Dec 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Current Assets | |||||||||||
| Cash & EquivalentsCash & Equiv. | 1.84M | 1.81M | 1.79M | 30.85M | 0.96M | 0.66M | 408.74M | 373.69M | 52.66M | 54.06M | |
| Short-term InvestmentsInvestments (Current) | 124.78M | 59.54M | 51.77M | 199.62M | 171.65M | ||||||
| Cash & Current Investments | 1.84M | 1.81M | 1.79M | 155.63M | 0.96M | 0.66M | 468.29M | 425.46M | 252.28M | 225.71M | |
| Receivables | 0.08M | 0.39M | 0.15M | 0.66M | |||||||
| Securities | 124.78M | 59.54M | 51.77M | 336.23M | 290.07M | ||||||
| Prepaid Assets | 0.02M | 0.01M | 0.25M | 2.98M | 0.21M | 0.15M | 7.50M | 6.55M | 14.08M | 16.01M | |
| Current Assets | 2.11M | 2.08M | 2.04M | 158.69M | 1.24M | 0.88M | 476.01M | 432.40M | 266.50M | 242.38M | |
| Non-Current Assets | |||||||||||
| Property, Plant & Equipment (Net) | 0.49M | 0.83M | 0.96M | 0.94M | 0.88M | ||||||
| Long-Term Investments | 185.21M | 187.65M | 190.20M | 192.45M | 194.44M | 196.51M | 136.62M | 118.42M | |||
| Other Non-Current Assets | 0.33M | 0.21M | 4.99M | 5.38M | 12.57M | 11.24M | 12.79M | ||||
| Non-Current Assets | 185.42M | 187.80M | 190.29M | 5.61M | 194.44M | 196.51M | 8.78M | 15.98M | 151.14M | 134.33M | |
| Assets | 0.33M | 187.53M | 189.87M | 192.33M | 164.30M | 195.68M | 197.39M | 484.79M | 448.38M | 417.65M | 376.71M |
| Liabilities | |||||||||||
| Current Liabilities | |||||||||||
| Accounts Payables | 0.01M | 3.07M | 2.52M | 3.65M | 1.37M | 12.09M | 6.73M | ||||
| Notes Payables | 0.07M | 0.48M | 0.09M | 0.11M | 0.69M | 0.53M | 0.72M | ||||
| Payables | 0.07M | 0.01M | 3.56M | 0.09M | 2.63M | 4.34M | 1.91M | 12.81M | 6.73M | ||
| Accumulated Expenses | 0.01M | 0.02M | 0.08M | 0.13M | 3.82M | 1.78M | 4.49M | 5.75M | 2.02M | 4.39M | |
| Other Accumulated Expenses | 0.17M | 0.18M | 0.24M | 0.55M | 0.20M | ||||||
| Current Leases | 0.51M | 0.52M | 0.54M | 0.55M | |||||||
| Total Current Liabilities | 0.40M | 0.02M | 0.08M | 0.13M | 19.58M | 1.87M | 2.63M | 35.71M | 35.04M | 43.26M | 51.63M |
| Non-Current Liabilities | |||||||||||
| Non-Current Deffered Revenue | 5.52M | 5.52M | 5.52M | 5.52M | 5.52M | 5.52M | |||||
| Preferred Stock Liabilities | 185.21M | 187.65M | 190.20M | 192.45M | 194.44M | 196.51M | |||||
| Operating Leases | 2.38M | 2.24M | 2.11M | 1.96M | |||||||
| Total Liabilities | 0.40M | 5.54M | 5.60M | 5.65M | 19.58M | 7.39M | 8.15M | 38.09M | 37.28M | 45.37M | 53.59M |
| Shareholder's Equity | |||||||||||
| Total Debt | 0.07M | 0.48M | 0.09M | 0.11M | 0.69M | 0.53M | 0.72M | ||||
| Common Equity | -115.64M | -128.87M | -143.44M | -159.21M | -178.64M | -200.03M | -227.73M | 510.00M | 411.10M | 372.28M | 323.11M |
| Liabilities and Shareholders Equity | 0.33M | 187.53M | 189.87M | 192.33M | 164.30M | 195.68M | 197.39M | 484.79M | 448.38M | 417.65M | 376.71M |
| Retained Earnings | -0.09M | -3.22M | -3.37M | -3.52M | -222.52M | -6.15M | -7.27M | 764.43M | 767.64M | 771.93M | 779.19M |
| Preferred Shares | 323.36M | 10.00M |